FDA Approves Omidubicel for Blood Cancer Patients Needing Stem Cell Transplant
The FDA has approved omidubicel for patients with blood cancers requiring allogeneic hematopoietic stem cell transplant (HSCT).
The FDA has approved omidubicel for patients with blood cancers requiring allogeneic hematopoietic stem cell transplant (HSCT).